Published in Int J Cancer on June 04, 2015
DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. Asian J Androl (2016) 0.81
A four-gene signature predicts survival in clear-cell renal-cell carcinoma. Oncotarget (2016) 0.76
Deletion of 8p is an independent prognostic parameter in prostate cancer. Oncotarget (2016) 0.75
Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis. Thorac Cancer (2017) 0.75
Deletion of 18q is a strong and independent prognostic feature in prostate cancer. Oncotarget (2016) 0.75
PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget (2017) 0.75
Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. BMC Cancer (2017) 0.75
Loss of heterozygosity on chromosome 16q increases relapse risk in Wilms' tumor: a meta-analysis. Oncotarget (2017) 0.75
A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy. J Urol (2014) 2.76
Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol (2017) 1.46
Histoscanning has low sensitivity and specificity for seminal vesicle invasion. Urology (2014) 1.46
Wound dehiscence in a sample of 1 776 cystectomies: identification of predictors and implications for outcomes. BJU Int (2015) 1.40
Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer. Int J Urol (2016) 1.39
TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur Urol (2014) 1.01
BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nat Genet (2014) 0.98
Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Mod Pathol (2014) 0.98
Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. Int J Cancer (2014) 0.95
Outcomes of Ventral Onlay Buccal Mucosa Graft Urethroplasty in Patients after Radiotherapy. J Urol (2015) 0.88
Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. Urol Oncol (2015) 0.87
βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am J Pathol (2013) 0.86
High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol (2015) 0.86
The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Urology (2015) 0.84
Socioeconomic status and health-related quality of life among patients with prostate cancer 6 months after radical prostatectomy: a longitudinal analysis. BMJ Open (2016) 0.82
Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol (2013) 0.82
The impact of resident involvement in male one-stage anterior urethroplasties. Urology (2015) 0.82
An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. BJU Int (2015) 0.81
Causes of hospital readmissions after urologic cancer surgery. Urol Oncol (2015) 0.81
Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer. Cancer Res (2015) 0.79
Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. Urol Oncol (2014) 0.79
Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urol Oncol (2014) 0.79
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep (2016) 0.78
Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol (2014) 0.78
Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. PLoS One (2015) 0.78
Redo buccal mucosa graft urethroplasty: success rate, oral morbidity and functional outcomes. BJU Int (2016) 0.77
Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis. World J Urol (2016) 0.77
Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genet (2014) 0.77
Prognostic relevance of postoperative platelet count in upper tract urothelial carcinoma after radical nephroureterectomy. Eur J Cancer (2014) 0.77
Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers. Int J Cancer (2015) 0.77
Direct Vision Internal Urethrotomy for Short Anterior Urethral Strictures and Beyond: Success Rates, Predictors of Treatment Failure and Recurrence Management. Urology (2017) 0.77
Patterns of ALK expression in different human cancer types. J Clin Pathol (2014) 0.76
Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma. Childs Nerv Syst (2015) 0.76
Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. Prostate (2016) 0.76
Detailed Quantification of High-grade Cancer Allows Precise Prediction of Prostate Cancer Prognosis. Eur Urol (2015) 0.75
Inpatients hypospadias care: trends and outcomes from the American nationwide inpatient sample. Korean J Urol (2015) 0.75
Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. Oncotarget (2016) 0.75
Female with bladder cancer: what and why is there a difference? Transl Androl Urol (2016) 0.75
p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget (2016) 0.75
Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. Int J Oncol (2015) 0.75
A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. Int J Cancer (2016) 0.75
Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. World J Urol (2016) 0.75
Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget (2017) 0.75
The effect of AB0 and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol (2017) 0.75
Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Clin Genitourin Cancer (2017) 0.75
North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. Prostate (2017) 0.75
Outcomes of single- vs double-cuff artificial urinary sphincter insertion in low- and high-risk profile male patients with severe stress urinary incontinence. BJU Int (2016) 0.75
Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int (2015) 0.75
Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urol Oncol (2016) 0.75
Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. BJU Int (2017) 0.75
Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer (2015) 0.75
Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. Eur Urol Focus (2016) 0.75
Substitution Urethroplasty with Closure Versus Nonclosure of the Buccal Mucosa Graft Harvest Site: A Randomized Controlled Trial with a Detailed Analysis of Oral Pain and Morbidity. Eur Urol (2017) 0.75
Differences in Recurrence Rate and De Novo Incontinence after Endoscopic Treatment of Vesicourethral Stenosis and Bladder Neck Stenosis. Front Surg (2017) 0.75
Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder. Urol Oncol (2016) 0.75
Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget (2017) 0.75
Local Therapy Improves Survival in Metastatic Prostate Cancer. Eur Urol (2017) 0.75